NCT01174407

Brief Summary

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 19, 2008

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 3, 2010

Completed
Last Updated

August 3, 2010

Status Verified

August 1, 2010

Enrollment Period

1.2 years

First QC Date

November 19, 2008

Last Update Submit

August 2, 2010

Conditions

Age-Related Macular Degeneration

Outcome Measures

Primary Outcomes (1)

  • determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration

    1 day

Secondary Outcomes (1)

  • expression rates of on AMD-patients and a healthy control group

    1 year

Study Arms (1)

cd35

Other: cd 35, cd21, cd55

Interventions

cd 35, cd21, cd55OTHER

Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient

cd35

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with exudative age-related macular degeneration, over 55

You may qualify if:

  • Man and women over 18 years old
  • Filled out informed consent
  • Diagnosis of non-exudative/ exudative age related macular degeneneration

You may not qualify if:

  • Inherited retinal diseases
  • Other acquired retinal/ macular
  • Missing informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rudolf Foundation Clinic

Vienna, Vienna, 1030, Austria

Location

Related Publications (1)

  • Haas P, Aggermann T, Nagl M, Steindl-Kuscher K, Krugluger W, Binder S. Implication of CD21, CD35, and CD55 in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2011 Sep;152(3):396-399.e1. doi: 10.1016/j.ajo.2011.02.017. Epub 2011 Jun 12.

    PMID: 21669404DERIVED

MeSH Terms

Conditions

Macular Degeneration

Interventions

Receptors, Complement 3dCD55 Antigens

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Receptors, ComplementReceptors, ImmunologicReceptors, Cell SurfaceMembrane ProteinsProteinsAmino Acids, Peptides, and ProteinsReceptors, VirusGPI-Linked ProteinsMembrane GlycoproteinsGlycoproteinsGlycoconjugatesCarbohydratesLipid-Linked Proteins

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 19, 2008

First Posted

August 3, 2010

Study Start

September 1, 2008

Primary Completion

December 1, 2009

Study Completion

August 1, 2010

Last Updated

August 3, 2010

Record last verified: 2010-08

Locations

AU(1)